Schedule of anti-dilutive weighted average shares (Details) - shares |
6 Months Ended | |
|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Basic And Diluted Incomeloss Per Share | ||
| Convertible loan notes – assuming all loan notes are converted to equity (including all warrants are fully exercised) | 33,768 | |
| TC BioPharm Limited Enterprise Management Incentive Plan 2014 | 106,585 | |
| 2021 Share Option Scheme | 52,305 | |
| Warrants issued at the time of the IPO | 318,443 | |
| Options to subscribe for ordinary shares at a future date based on certain clinical and commercial milestones | 15,891 | |
| Dilutive effect securities | 404,516 | 122,476 |
| X | ||||||||||
- Definition Dilutive effect of incentive plan. No definition available.
|
| X | ||||||||||
- Definition Dilutive effect of options to subscribe ordinary shares. No definition available.
|
| X | ||||||||||
- Definition Dilutive effect of warrants issued. No definition available.
|
| X | ||||||||||
- Definition Dilutive effect securities. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of dilutive potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|